A5038974730- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Renal and related cancers
- Prostate Cancer Diagnosis and Treatment
- Renal and Vascular Pathologies
- Prostate Cancer Treatment and Research
- Multiple and Secondary Primary Cancers
- Pediatric Urology and Nephrology Studies
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Organ Donation and Transplantation
- Urologic and reproductive health conditions
- Chronic Kidney Disease and Diabetes
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- MRI in cancer diagnosis
- Health Systems, Economic Evaluations, Quality of Life
- Urological Disorders and Treatments
- Pancreatic and Hepatic Oncology Research
- Urinary Bladder and Prostate Research
- Sexual function and dysfunction studies
- Hormonal and reproductive studies
- Cancer Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Radiomics and Machine Learning in Medical Imaging
Vita-Salute San Raffaele University
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2016-2025
IRCCS Ospedale San Raffaele
2016-2025
San Raffaele University of Rome
2014-2024
Institute of Experimental Endocrinology of the Slovak Academy of Sciences
2018-2024
European Association of Urology
2021
Urologic Research Institute
2021
University of Technology, Jamaica
2020
University of Richmond
2020
The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management RCC. To present a summary 2022 RCC guideline, which is based on standardised methodology including systematic reviews (SRs) provides transparent reliable evidence For update, new literature search was carried out with cutoff date May 28, 2021, covering Medline, EMBASE, Cochrane databases. data focused randomised controlled trials...
Relative to radical nephrectomy (RN), partial (PN) performed for renal cell carcinoma (RCC) may protect from non-cancer-related deaths. The authors tested this hypothesis in a cohort of PN and RN patients.The Surveillance, Epidemiology, End Results-9 database allowed identification 2198 (22.4%) 7611 (77.6%) patients treated T1aN0M0 RCC between 1988 2004. Analyses matched age, year surgery, tumor size, Fuhrman grade addressed the effect type (RN vs PN) on overall mortality (Cox regression...
Different modalities of percutaneous thermal ablation (PTA) have been used as possible minimally invasive nephron-sparing treatments for small renal masses (SRMs). The present study aimed to compare long-term outcomes two guidelines-recommended ablative techniques, cryotherapy (CRYO) and radiofrequency (RFA). Data patients with single cT1 solid mass undergoing CRYO or RFA between 2004 2020 were retrospectively retrieved from a multi-institutional international database. Oncologic included...
We evaluated the association of soft tissue surgical margins with characteristics and outcomes patients treated radical cystectomy for urothelial carcinoma bladder.We retrospectively collected data 4,410 pelvic lymphadenectomy without neoadjuvant chemotherapy at 12 academic centers in United States, Canada Europe. A positive margin was defined as presence tumor inked areas on specimen.Positive were identified 278 (6.3%). On univariate analysis significantly associated advanced pT stage,...
We tested whether the combination of 4 established cell cycle regulators (p53, pRB, p21 and p27) could improve ability to predict clinical outcomes in a large multi-institutional collaboration patients with pT3-4N0 or pTany Npositive urothelial carcinoma bladder. also assessed molecular markers is superior any individual biomarker.The study comprised 692 bladder treated radical cystectomy bilateral lymphadenectomy (median followup 5.3 years). Scoring was performed using advanced imaging...
Several small single-center studies have reported a prognostic role for Ki-67 labeling index in advanced urothelial carcinoma of the urinary bladder. To investigate whether was useful biomarker oncological outcome after radical cystectomy carcinoma, we assessed its expression tumor tissue from 713 patients treated with and bilateral lymphadenectomy at six centers. A high independently associated established features aggressive disease recurrence, cancer-specific survival. Addition improved...
OBJECTIVE To assess the magnitude of effect histological subtype (HS, three most common being clear cell, papillary and chromophobe) on cause-specific mortality (CSM) from renal cell carcinoma (RCC). PATIENTS AND METHODS Univariable multivariable Cox regression models included data 11 618 patients treated with nephrectomy between 1988 2004 in nine Surveillance Epidemiology End Results registries. We tested whether HS represents an independent predictor CSM, adds to ability other variables...